Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of SHR-1703 Injection via PFS vs AI in Healthy Participants
NCT07701239Phase 1Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR-1703 in eosinophilic asthma (EoA) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Peak Concentration, Area Under the Serum Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EoA)
Beyond the preview
Go deeper on NCT07701239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701239.